A comparison between the effects of glucantime, topical trichloroacetic acid 50% plus glucantime, and fractional laser plus glucantime on cutaneous leishmaniasis lesions

Journal of Isfahan Medical School

Volumn 30, Issue 221, 2013, Pages 2450-2459

  Nilforoushzadeh, Mohammad Ali ^a   Siadat, Amir Hosein ^b   Ansari, Nazli ^b   Haftbaradaran, Elaheh ^b   Ahmadi, Elham ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cutaneous leishmaniasis; Fractional laser; Glucantime; Meglumine antimoniate; Trichloroacetic acid

Indexed keywords

EID: 84940318973     PISSN: 10277595     EISSN: 1735854X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Nilfroushzadeh MA, Sadeghian G. Cutaneous leishmaniasis. Isfahan, Iran: Isfahan University of Medical Sciences; 2002. 45-7. [In Persian].
2. Nilforoushzadeh MA, Jaffary F, Derakhshan R, Haftbaradaran E. Comparison between intralesional meglumine antimoniate and combination of trichloroacetic acid 50% and intralesional meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Skin and Leishmaniasis 2010; 1(1): 18-22.
3. Nilforoushzadeh MA, Jaffary F, Moradi Sh, Derakhshan R, Haftbaradaran E. Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis. BMC Complement Altern Med 2007; 7: 13.
4. Sadeghian G, Nilforoushzadeh MA. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45(7): 819-21.
5. World Health Organization. Tropical disease research. 12th program report. UNDP/ World bank/ WHO special program for research and training disease (TDR). Geneva, Switzerland: WHO; 1995. p.135-49.
6. Asilian A. Cutaneous leishmaniasis treatmentand prevention methods. Isfahan, Iran: Isfahan University of Medical Sciences; 1992. p. 52-68. [In Persian].
7. Momeni A, Amin Javaheri M, Tajdidi M, Emamjomeh M. Theraputic and side effects of Glucantime in cutaneous leishmaniasis. Nabz 1993; 2: 5-10.
8. Lerner EA, Grevelink SA. Leishmaniasis. In: Arndt KA, Robinson JK, Leboit PE, Wintroub BU, editors. Cutaneous medicine and surgery. Philadelphia, PA: Saunders; 1996. p. 1163-70.
9. Vega Lopez F, Hay RJ. Parasitic worm and protozoa. In: Burns T, Breathnach S, Cox N, Griffiths CH, editors. Rooks text book of dermatology. 7th ed. Malden, MA: Blackwell Science; 2004. p. 3238-9.
10. Nilforooshzadeh MA, Reisszadeh MR, Jafari F. Topical trichloroacetic acid compared with intralesional Glucantime injection in the treatment of acute wet cutaneous leishmaniasis: an open clinical trial. Iran J Dermatol 2002; 6(22): 34-9.
11. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol 1996; 14(5): 425-31.
12. Glogau RG, Matarasso SL. Chemical peels. Trichloroacetic acid and phenol. Dermatol Clin 1995; 13(2): 263-76.
13. Nilfroushzadeh MA, Jafary F, Reiszadeh MR. Comparative effect of topical trichloroactic acid and Intralesional meglumin antimovaniate in the treatment of acute cutaneous leishmaniasis. Int J pharm 2006; 2(6): 633-6.
14. Neaman KC, Baca ME, Piazza RC, ILI, VanderWoude DL, Renucci JD. Outcomes of fractional CO2 Laser application in aesthetic surgery: a retrospective review. Aesthet Surg J 2010; 30(6): 845-52.
15. Rivera AE. Acne scarring: a review and current treatment modalities. J Am Acad Dermatol 2008; 59(4): 659-76.
16. Alster TS, Tanzi EL, Lazarus M. The use of fractional Laser photothermolysis for the treatment of atrophic scars. Dermatol Surg 2007; 33(3): 295-9.
17. Medical Letter on the CDC and FDA. Surgery; reliant technologies announces groundbreaking clinical results for deep dermal tissue removal-a first of its kind. Atlanta, GA: 2007. p. 56
18. Medical Letter on the CDC and FDA. Laser system; reliant technologies announces Canadian launch of Fraxel re:pair (R) Laser: a new class of treatment Therapy for CO2 Laser resurfacing [cited 2008 Sep 1]; Available from: URL: http://www.newsrx.com/health-articles/ 1222594.html
19. Kono T, Chan HH, Groff WF, Manstein D, Sakurai H, Takeuchi M, et al. Prospective direct comparison study of fractional resurfacing using different fluences and densities for skin rejuvenation in Asians. Lasers Surg Med 2007; 39(4): 311-4.
20. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43(4): 281-3.
21. Faghihi G, Tavakoli-kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 2003; 28(1): 13-6.
22. Nilforoushzadeh MA, Sadeghian G, Jaffary F, Ziaei H, Shirani-Bidabad L, Mahzoni P. Successful treatment of lupoid cutaneous leishmaniasis with glucantime and topical trichloroacetic acid (a case report). Korean J Parasitol 2008; 46(3): 175-7.
23. Nilforoushzadeh MA, Jaffari F, Haftbaradaran E, Nilforoushzadeh A. The efficacy of 5% trichloroacetic acid cream in the treatment of cutaneous leishmaniasis lesions. J Dermatolog Treat 2012; 23(2): 136-9.
24. Sadeghian G, Nilfroushzadeh MA, Iraji F. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clin Exp Dermatol 2007; 32(4): 371-4.
25. Ardhali S, Rezaei K, Nadim A. Leishmaniasis parasite and leishmaniasis. Tehran, Iran: Iran University Press; p. 149-60. [In Persian].
26. Chwalek J, Goldberg DJ. Ablative skin resurfacing. Curr Probl Dermatol 2011; 42: 40-7.